KR102723194B1 - Cftr 조절제 및 이의 사용 방법 - Google Patents

Cftr 조절제 및 이의 사용 방법 Download PDF

Info

Publication number
KR102723194B1
KR102723194B1 KR1020187021185A KR20187021185A KR102723194B1 KR 102723194 B1 KR102723194 B1 KR 102723194B1 KR 1020187021185 A KR1020187021185 A KR 1020187021185A KR 20187021185 A KR20187021185 A KR 20187021185A KR 102723194 B1 KR102723194 B1 KR 102723194B1
Authority
KR
South Korea
Prior art keywords
substituted
unsubstituted
nhc
och
nhnh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187021185A
Other languages
English (en)
Korean (ko)
Other versions
KR20180101415A (ko
Inventor
앨런 버크만
마크 에이치. 레빈
오누르 실
Original Assignee
더 리젠츠 오브 더 유니버시티 오브 캘리포니아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 filed Critical 더 리젠츠 오브 더 유니버시티 오브 캘리포니아
Publication of KR20180101415A publication Critical patent/KR20180101415A/ko
Application granted granted Critical
Publication of KR102723194B1 publication Critical patent/KR102723194B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Prostheses (AREA)
KR1020187021185A 2015-12-24 2016-12-23 Cftr 조절제 및 이의 사용 방법 Active KR102723194B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562387591P 2015-12-24 2015-12-24
US62/387,591 2015-12-24
PCT/US2016/068561 WO2017112947A1 (en) 2015-12-24 2016-12-23 Cftr regulators and methods of use thereof

Publications (2)

Publication Number Publication Date
KR20180101415A KR20180101415A (ko) 2018-09-12
KR102723194B1 true KR102723194B1 (ko) 2024-10-28

Family

ID=59091233

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187021185A Active KR102723194B1 (ko) 2015-12-24 2016-12-23 Cftr 조절제 및 이의 사용 방법

Country Status (15)

Country Link
US (2) US20190031630A1 (https=)
EP (1) EP3394083B9 (https=)
JP (1) JP6894902B2 (https=)
KR (1) KR102723194B1 (https=)
CN (1) CN108699107B (https=)
AU (2) AU2016377782B2 (https=)
CL (1) CL2018001714A1 (https=)
CO (1) CO2018007239A2 (https=)
ES (1) ES2901002T3 (https=)
IL (2) IL299924B2 (https=)
PL (1) PL3394083T3 (https=)
PT (1) PT3394083T (https=)
RU (1) RU2742934C2 (https=)
WO (1) WO2017112947A1 (https=)
ZA (1) ZA201804228B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX383072B (es) 2015-12-24 2025-03-13 Univ California Reguladores del cftr y métodos para su uso
IT201700085714A1 (it) * 2017-07-26 2019-01-26 Luigi Maiuri Approccio terapeutico per il trattamento e/o prevenzione di condizioni di sensibilità al glutine.
JP2020531511A (ja) * 2017-08-24 2020-11-05 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア 眼球用医薬組成物
FR3096890B1 (fr) * 2019-06-07 2021-05-14 H4 Orphan Pharma Utilisation d’une molécule opioïde pour traiter l’œil sec et l’œil allergique.
US20220071549A1 (en) * 2020-09-08 2022-03-10 The Regents Of The University Of California Apparatus, systems and methods of use for ocular surface potential difference measurement
AU2021363703A1 (en) 2020-10-23 2023-06-22 S2Cbio Inc. Cftr modulator compounds, compositions, and uses thereof
CN113527225B (zh) * 2021-07-15 2022-11-18 南昌大学 一种丙烯酰噻二唑衍生物及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140080825A1 (en) 2004-01-30 2014-03-20 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
WO2015196071A1 (en) 2014-06-19 2015-12-23 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr activity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010042298A (ko) 1998-03-31 2001-05-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 인자 Ｘａ 및 트롬빈과 같은 세린 프로테아제억제제로서의 퀴녹살리논
AU2003277162C1 (en) * 2002-09-30 2009-12-24 The Regents Of The University Of California Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
MXPA06008606A (es) * 2004-01-30 2007-04-13 Vertex Pharma Moduladores de transportadores con casete de union a atp.
US20090105240A1 (en) * 2007-10-17 2009-04-23 Tomas Mustelin Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same
EP2247580B1 (en) 2008-03-05 2015-07-08 Merck Patent GmbH Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes
US8314239B2 (en) 2008-10-23 2012-11-20 Vertex Pharmaceutical Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2010073011A2 (en) * 2008-12-23 2010-07-01 Betagenon Ab Compounds useful as medicaments
WO2012092471A2 (en) * 2010-12-29 2012-07-05 Development Center For Biotechnology Novel tubulin inhibitors and methods of using the same
CA2942386A1 (en) * 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140080825A1 (en) 2004-01-30 2014-03-20 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
WO2015196071A1 (en) 2014-06-19 2015-12-23 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr activity

Also Published As

Publication number Publication date
US20200140402A1 (en) 2020-05-07
EP3394083B1 (en) 2021-09-01
AU2016377782B2 (en) 2021-07-29
CN108699107B (zh) 2022-05-10
IL299924A (en) 2023-03-01
IL299924B2 (en) 2025-01-01
AU2021257948A1 (en) 2021-11-25
EP3394083A1 (en) 2018-10-31
US20190031630A1 (en) 2019-01-31
ZA201804228B (en) 2020-09-30
CL2018001714A1 (es) 2018-10-26
US11192869B2 (en) 2021-12-07
ES2901002T3 (es) 2022-03-21
RU2018126959A3 (https=) 2020-08-20
NZ743720A (en) 2024-08-30
CN108699107A (zh) 2018-10-23
AU2016377782A1 (en) 2018-07-12
CO2018007239A2 (es) 2018-07-19
IL299924B1 (en) 2024-09-01
BR112018012927A2 (en) 2018-12-11
WO2017112947A1 (en) 2017-06-29
IL260210B2 (en) 2023-06-01
JP6894902B2 (ja) 2021-06-30
IL260210A (en) 2018-07-31
RU2742934C2 (ru) 2021-02-11
EP3394083B9 (en) 2022-04-27
PL3394083T3 (pl) 2022-01-17
AU2021257948B2 (en) 2023-11-30
KR20180101415A (ko) 2018-09-12
ES2901002T9 (es) 2022-06-20
JP2018538354A (ja) 2018-12-27
CA3009531A1 (en) 2017-06-29
PT3394083T (pt) 2021-12-07
EP3394083A4 (en) 2019-09-04
RU2018126959A (ru) 2020-01-24

Similar Documents

Publication Publication Date Title
KR102723194B1 (ko) Cftr 조절제 및 이의 사용 방법
JP7297827B2 (ja) Ｃｆｔｒ制御因子及びこの使用方法
KR102743295B1 (ko) Cftr 조절제 및 이의 이용 방법
CA3009531C (en) 5-substituted [1,3,4]thiadiazol-2-amido derivatives and use as cftr reg ulators

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180723

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211222

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231218

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240807

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20241024

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20241024

End annual number: 3

Start annual number: 1

PG1601 Publication of registration